Please use this identifier to cite or link to this item:

Title3D biosensors in advanced medical diagnostics of high mortality diseases
Author(s)Rebelo, Rita Daniela Nogueira
Barbosa, Ana I.
Caballero, David
Kwon, Il Keun
Oliveira, J. M.
Kundu, Subhas C
Reis, R. L.
Correlo, V. M.
Keywords3D biosensors
Cardiovascular diseases
Issue dateApr-2019
JournalBiosensors and Bioelectronics
CitationRebelo R., Barbosa A. I., Caballero D., Kwon I. K., Oliveira J. M., Kundu S. C., Reis R. L., Correlo V. M. 3D biosensors in advanced medical diagnostics of high mortality diseases, Biosensors and Bioeletronics, Vol. 130, pp. 20-39, doi:10.1016/j.bios.2018.12.057, 2019
Abstract(s)Cardiovascular diseases, cancer, and diabetes are high mortality diseases, which account for almost two thirds of all deaths worldwide. Their early detection and continuous evaluation is fundamental for an improved patient prognosis and reduced socioeconomic impact. Current biosensor technologies are typically based on the analysis of whole blood samples from patients for the detection of disease-specific biomarkers. However, these technologies display serious shortcomings, such as reduced sensitivity and dynamic range, limited in vivo applicability, and lack of continuous monitoring. There is the urgent need for new diagnostic and treatment follow-up tools, which allow for the early detection of the pathology as well as for the continuous monitoring of the physiological response to specific therapies. During the last years, a new generation of biosensor technologies with improved performance has emerged in the biomedical sector. The combination of advanced biomaterial methods, biochemical tools, and micro/nanotechnology approaches has resulted in the development of innovative three-dimensional (3D) biosensor platforms for advanced medical diagnosis. In this review, we report the most recent advances in the field of 3D biosensors for clinical applications, focusing on the diagnosis and monitoring of cardiovascular diseases, cancer, and diabetes. We discuss about their clinical performance compared to standard biosensor technologies, their implantable capability, and their integration into microfluidic devices to develop clinically-relevant models. Overall, we anticipate that 3D biosensors will drive us toward a new paradigm in medical diagnosis, resulting in real-time in vivo biosensors capable to significantly improve patient prognosis.
Publisher version
AccessOpen access
Appears in Collections:3B’s - Artigos em revistas/Papers in scientific journals

Files in This Item:
File Description SizeFormat 
19716-1-s2.0-S0956566319300259-main (1).pdf2,72 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID